Skip to content
Open access

Incremental Value of CSF Biomarker-Integrated Classification of Cerebral Amyloid Angiopathy

Sep 2026 · medRxiv · 0 citations
Medicine

TL;DR

The CSF biomarker-integrated reclassification significantly improved the distinction between subgroups regarding CAA- and arteriosclerosis-related MRI features and support a future transition toward an integrated biological-radiological framework, which may refine in vivo CAA diagnosis, particularly in mixed SVD.

Abstract

Background: The Boston Criteria v2.0 represent the gold standard for diagnosing Cerebral Amyloid Angiopathy (CAA), but their application is currently precluded in mixed small vessel disease (SVD), where deep and lobar hemorrhages coexist. The aims of this study are: (i) to determine which cerebrospinal fluid (CSF) biomarker (A{beta}42, A{beta}40, A{beta}42/40 ratio) is the best candidate to support the CAA diagnosis; (ii) to define a data-driven cut-off, and (iii) to explore if a biomarker-integrated classification significantly improves the phenotypical concordance with the suspected predominant SVD (CAA vs. arteriosclerosis). Methods: We analyzed data from a retrospective multicenter cohort of patients with suspected CAA, defined as probable CAA (Boston criteria v2.0) but allowing deep hemorrhagic lesions, and with available CSF biomarkers. We visually quantified MRI-visible SVD markers (e.g., cerebral microbleeds [CMB], cortical superficial siderosis [cSS], lacunes) and their association with MRI-visible SVD features. We employed a Gaussian Mixture Model (GMM) to identify a data-driven threshold for amyloid positivity (A+). Then, we compared the prevalence of MRI-visible manifestations of SVD between subgroups applying different frameworks, namely the current MRI-based classification (probable CAA vs. mixed SVD) and a CSF biomarker-integrated classification (A+ vs. A-). Results: We enrolled 121 patients (age: 72 [66-77] years; 60% probable CAA, 40% mixed SVD with suspected CAA). The CSF A{beta}42/40 ratio showed a bimodal distribution and consistent associations with all CAA-specific radiological features. The CSF biomarker-integrated reclassification, particularly using the GMM cut-off, significantly improved the distinction between subgroups regarding CAA- and arteriosclerosis-related MRI features (e.g., cSS presence: probable CAA vs. mixed SVD: aOR=2.84 [95%CI 1.27-6.39], p=0.011; A+ vs. A-: aOR=12.68 [95%CI 4.31-37.32], p<0.001; deep lacunes presence: probable CAA vs. mixed SVD: aOR=0.20 [95%CI 0.08-0.50], p<0.001; A+ vs. A-: aOR=0.04 [95%CI 0.01-0.11], p<0.001). Notably, patients classified as A+ never demonstrated more than four deep CMBs. Discussion: A CSF biomarker-integrated classification may improve the classification of CAA compared with the current MRI-based framework. These findings are cohort-specific and would benefit from further validation, especially with a neuropathological reference. Still, these results support a future transition toward an integrated biological-radiological framework, which may refine in vivo CAA diagnosis, particularly in mixed SVD.

Read PDF

Similar papers

Sep 2026

Evaluation of Disease Severity Using CSF Biomarkers in Patients With Probable Cerebral Amyloid Angiopathy.

Findings suggest that CSF Aβ levels may reflect vascular amyloid burden rather than downstream neurodegeneration, and lower CSF Aβ40 and Aβ42 levels are associated with established MRI markers of disease severity, independently of clinical presentation and concomitant Alzheimer-like profile.

Quentin Beaufort, Camille Charbonnier, Philippine Ruellan et al. · 0 citations
Oct 2026

Epilepsy as a marker of cognitive decline in cerebral amyloid angiopathy: Evidence from a large multi-institutional cohort.

INTRODUCTION Cerebral amyloid angiopathy (CAA) is an amyloid mediated cortical and leptomeningeal small-vessel disease that commonly presents with lobar intracerebral hemorrhage, cognitive impairment, and transient neurological symptoms. Epilepsy occurs in 20-33 % of patients with CAA, but their association with cognit...

Y. Khand, S. Vallamchetla, Anshum Patel et al. · 1 citation
Open access Oct 2026

Circulating microRNAs reflect hemorrhagic MRI markers in cerebral amyloid angiopathy.

BACKGROUND Cerebral amyloid angiopathy is a major cause of intracerebral hemorrhage in older individuals. Although cerebral microbleeds (CMBs) and cortical superficial siderosis (cSS) aid MRI diagnosis they offer limited pathophysiological insight. MicroRNAs (miRs) regulate microvascular function and may serve as nonin...

J. Duijs, E. Koemans, N. Verwey et al. · 0 citations
Open access Oct 2026

Exploratory synergistic diagnostic value of CSF neurofilament light chain and topographic cortical atrophy in differentiating cerebral amyloid angiopathy from Alzheimer's disease - a pilot study.

BACKGROUND Differentiating Cerebral Amyloid Angiopathy (CAA) from Alzheimer's disease (AD) in vivo is challenging due to overlapping amyloid pathology and limited availability sensitivity of hemorrhagic markers in memory clinic settings. We investigated whether integrating regional cortical atrophy with cerebrospinal f...

R. Jansen, P. Arndt, Jascha Brüggemann et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.